Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.530
-0.010 (-0.65%)
Feb 21, 2025, 4:00 PM EST - Market closed
Cellectis Employees
As of December 31, 2023, Cellectis had 221 total employees, including 216 full-time and 5 part-time employees. The number of employees decreased by 16 or -6.75% compared to the previous year.
Employees
221
Change (1Y)
-16
Growth (1Y)
-6.75%
Revenue / Employee
$163,086
Profits / Employee
-$382,253
Market Cap
157.13M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
CLLS News
- 2 months ago - Cellectis: Poised To Start Answering Questions In 2025 - Seeking Alpha
- 2 months ago - Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB) - GlobeNewsWire
- 3 months ago - Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting - GlobeNewsWire
- 3 months ago - Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 - GlobeNewsWire
- 4 months ago - Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 - GlobeNewsWire
- 4 months ago - Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - GlobeNewsWire
- 6 months ago - Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety - GlobeNewsWire